covid_cell_1

Pharmafile.com’s weekly COVID-19 news round-up

pharmafile | November 11, 2020 | News story | Research and Development  

The COVID-19 news this week focuses on vaccines, with AstraZeneca committing to an agreement to deliver 22 million doses of its COVID-19 vaccine candidate to Argentina, while two more COVID-19 vaccine distribution deals have been signed by the Australian Government, reserving a further 50 million doses to potentially roll out to its citizens in the coming months.

In other news, Denmark is set to cull its 17 million mink population after it was found a mutation of coronavirus in the animal had spread to humans.

1. Denmark set to cull mink population after mutated strain of COVID-19 spreads to humans – Published on 05/11/20

Denmark is set to cull its 17 million mink population after it was found a mutation of coronavirus in the animal had spread to humans.

2. Novartis’ arthritis therapy shows no efficacy in hospitalised COVID-19 patients – Published on 06/11/20

Novartis has revealed that its arthritis drug, theinterleukin-1 beta inhibitor canakinumab, in combination with standard of care (SoC), failed to meet its main goal in the treatment of hospitalised patients with COVID-19 pneumonia and cytokine release syndrome (CRS).

3. Head of UK’s COVID-19 vaccine taskforce faces questions over biotech fund – Published on 09/11/20

Kate Bingham, the head of the British Government’s vaccine taskforce, faces scrutiny after it was revealed her venture capital firm has invested in companies developing coronavirus antibody cocktails.

4. Australia secures a further 50m COVID-19 vaccine doses from Novavax and Pfizer/BioNTech – Published on 05/11/20

Two more COVID-19 vaccine distribution deals have been signed by the Australian Government, reserving a further 50 million doses to potentially roll out to its citizens in the coming months.

5. Argentina secures 22 million COVID-19 vaccine doses from AstraZeneca and Oxford Uni – Published on 09/11/20

AstraZeneca has committed to an agreement to deliver 22 million doses of its COVID-19 vaccine candidate, co-developed in partnership with the University of Oxford, to Argentina.

Related Content

No items found

Latest content